No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
TI-CE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
CaT
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
VC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
GemOx
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
BEP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
EP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
VIP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
VAC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
VeIP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
TIP
Sensitive: A2 - Guideline
|
|
Germ Cell Tumors
Germ Cell Tumors
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
carboplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
etoposide IV
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Germ Cell Tumors
Germ Cell Tumors
|
paclitaxel + gemcitabine + oxaliplatin
Sensitive: A2 - Guideline
|
|
Germ Cell Tumors
Germ Cell Tumors
|
pembrolizumab
Sensitive: A2 - Guideline
|
BRCA1 mutation
BRCA1 mutation
|
Germ Cell Tumors
Germ Cell Tumors
|
olaparib
Sensitive: C1 - Off-label
|
XPA expression
XPA expression
|
Germ Cell Tumors
Germ Cell Tumors
|
cisplatin
Resistant: C3 – Early Trials
|
MTOR mutation
MTOR mutation
|
Germ Cell Tumors
Germ Cell Tumors
|
everolimus
Sensitive: C3 – Early Trials
|
KRAS amplification
KRAS amplification
|
Germ Cell Tumors
Germ Cell Tumors
|
MEK inhibitor
Sensitive: C3 – Early Trials
|
|
Germ Cell Tumors
Germ Cell Tumors
|
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
|
|
Germ Cell Tumors
Germ Cell Tumors
|
icotinib
Sensitive: C4 – Case Studies
|
BAX underexpression
BAX underexpression
|
Germ Cell Tumors
Germ Cell Tumors
|
cisplatin
Resistant: C4 – Case Studies
|
TP53 mutation
TP53 mutation
|
Germ Cell Tumors
Germ Cell Tumors
|
cisplatin
Resistant: C4 – Case Studies
|
|
Germ Cell Tumors
Germ Cell Tumors
|
icotinib
Sensitive: C4 – Case Studies
|
PLAC8 overexpression
PLAC8 overexpression
|
Germ Cell Tumors
Germ Cell Tumors
|
etoposide oral
Resistant: D – Preclinical
|
BRCA1 expression
BRCA1 expression
|
Germ Cell Tumors
Germ Cell Tumors
|
olaparib
Resistant: D – Preclinical
|
RAD51C expression
RAD51C expression
|
Germ Cell Tumors
Germ Cell Tumors
|
olaparib
Resistant: D – Preclinical
|
